<DOC>
	<DOCNO>NCT00720785</DOCNO>
	<brief_summary>Natural killer ( NK ) cell white blood cell limit ability kill cancer cell . This ability might enhance give 24 hour injection drug bortezomib . This study determine follow : - What dose NK cell give safely subject metastatic solid tumor leukemia . - The effectiveness side effect NK cell therapy - How body handle NK cell . People 18 70 year age solid tumor leukemia , standard treatment effective , may eligible study . Participants undergo follow procedure : Apheresis collect NK cell . For procedure , catheter ( plastic tube ) place vein subject arm . Blood flow vein cell separator machine , separate white cell blood component . The white cell extract rest blood return body second tube place vein arm . Chemotherapy drug pentostatin suppress immune system prevent attack NK cell infuse . Chemotherapy bortezomib increase NK cell function . Infusion NK cell . In dose-escalating study , successive group patient enter study receive increasingly high number cell determine high safe dose level . Up four dose level may study . Interleukin-2 drug therapy maintain NK cell activity . Evaluations therapy include : - Clinical assessment , history review medication - Blood draw routine research test . - Pharmacokinetics study NK infusion see body handle cell . For test , number NK cell blood measure time . This require draw 1 teaspoon blood 15 minute , 30 minute , 1 , 2 , 4 , 8 , 12 , 24 hour infusion ( day 1 ) ; every 24 hour day 2 7 , day 10 , 14 , 21 . - Bone marrow biopsy ( subject leukemia ) . - Chest x-ray . - CT scan , bone scan PET scan , indicate , disease evaluation . Subjects respond well one treatment cycle may eligible continue NK cell therapy .</brief_summary>
	<brief_title>Natural Killer Cells Bortezomib Treat Cancer</brief_title>
	<detailed_description>Natural killer ( NK ) cell innate immune lymphocyte identify expression CD56 surface antigen lack CD3 . Unlike antigen specific T cell , NK cell require presence specific tumor antigen recognition kill cancer cell . Our vitro study demonstrate pretreatment malignant cell bortezomib significantly enhance NK-mediated tumor cytotoxicity sensitize cell TNF-related apoptosis-inducing ligand ( TRAIL ) . TRAIL member tumor necrosis factor family cytokine promote apoptosis . Importantly , laboratory , vitro expand NK cell isolate patient metastatic cancer hematological malignancy exhibit significantly cytotoxicity tumor cell tumor pre-treated bortezomib compare untreated tumor control . These finding suggest drug-induced sensitization TRAIL could use novel strategy potentiate anticancer effect autologous adoptively infused NK cell patient cancer . Murine study conduct laboratory also establish bortezomib treatment sensitize tumor vivo kill adoptively infuse syngeneic NK cell ; murine renal cell carcinoma line ( RENCA ) tumor BALB/c mouse grow significantly slow survival prolong syngeneic NK cell infusion give follow bortezomib treatment compare mice receive NK cell infusion alone bortezomib alone . This anti-tumor effect potentiate eradicate T-regulatory cell prior adoptive NK cell infusion administer interleukin-2 adoptive NK cell infusion . Recently , laboratory develop technique vitro isolation expansion NK cell level suitable treatment cancer patient . Furthermore , also establish good viability sterility expand NK cell , compare fresh NK cell , increase surface expression TRAIL enhance cytotoxicity tumor cell . We therefore propose non-randomized , Phase I , dose escalate study design evaluate safety anti- tumor effect escalate dos adoptively infuse ex vivo expand autologous natural killer ( NK ) cell metastatic cancer hematological malignancy sensitize NK TRAIL cytotoxicity Bortezomib . The primary study objective determine safety ( maximum tolerate dose ) escalate NK cell dose adoptively infused ex vivo expand autologous NK cell subject treatment refractory metastatic tumor hematological malignancy sensitize NK cell cytotoxicity use bortezomib . Secondary objective include anti-neoplastic effect treatment regimen ( assess use standard disease specific response criterion ) toxicity profile associate extended cycle protocol therapy . The primary endpoint assess day 21 ( 3 week Day 0 NK cell infusion ) .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . Diagnosed histologically confirm metastatic solid tumor cancer lung ( small cell non small cell ) , prostate ( adenocarcinoma ) , colorectum , kidney ( renal cell carcinoma ) , pancreas ( adenocarcinoma ) , malignant melanoma , metastatic Ewing 's sarcoma , metastatic epithelial neoplasm adenocarcinoma unknown primary , disease confirm metastatic unresectable standard curative beneficial treatment longer effective OR Diagnosed hematological malignancy ( multiple myeloma , [ MM ] chronic myelogenous leukemia [ CML ] chronic lymphocytic leukemia [ CLL ] small lymphocytic lymphoma [ SLL ] ) disease resistant refractory standard therapy CLL/SLL patient require failed prior treatment least one nucleoside analogue . Myeloma patient require disease progress follow treatment bortezomib . 2 . At least 4 week since prior systemic therapy ( exclude corticosteroid therapy ) treat underlying malignancy ( standard investigational ) . NOTE : subject FDAapproved tyrosine kinase inhibitor target therapy RCC mTOR inhibitor evidence disease progression therapy may continue medicine time study enrollment ( accelerated disease progression follow discontinuation drug describe ) . 3 . At least 2 week since prior palliative radiotherapy . 4 . Ages great equal 18 year less equal 70 year . 5 . Evidence progressive disease 3month interval . 6 . RBC transfusion independent ( solid tumor patient ) . EXCLUSION CRITERIA : 1 . Disease evaluable radiographically ( applies solid tumor patient ) . 2 . Disease involve great 25 % liver radiographically ( estimate base review liver lesion see CT scan ) . 3 . History allogeneic hematopoietic stem cell transplant . 4 . Brain metastasis ( exception patient single brain metastasis le 1cm treat either sterotactic gamma knife radiotherapy ) due poor prognosis potential neurological dysfunction would confound evaluation neurological adverse event ) . 5 . Peripheral neuropathy grade great 1 , would require reduction bortezomib dose . 6 . Acute diffuse infiltrative pulmonary disease . 7 . Acute pericardial disease . 8 . Life expectancy le 3 month . 9 . ECOG performance status 2 , 3 4 . 10 . Uncontrolled concurrent illness include , limited , symptomatic congestive heart failure , unstable angina pectoris , life threaten cardiac arrhythmia . Patients symptoms coronary artery disease , cardiac arrhythmia abnormal thallium stress test must evaluate cleared cardiology prior enrollment . 11 . Ongoing active infection 12 . Contraindication administration pentostatin , bortezomib , and/or interleukin2 . 13 . Allergy hypersensitivity bortezomib , boron mannitol history . 14 . Concurrent use corticosteroid . 15 . For tumor type : Marrow function characterize Absolute neutrophil count le 500/mcL ( must present growth factor ) Organ function characterize Total bilirubin great 3 time upper limit normal AST ( SGOT ) /ALT ( SGPT ) great 4 time upper limit normal Creatinine clearance le 50 cc/min base 24 hour urine collection Left ventricular ejection fraction le 40 % echocardiogram ( ECHO ) Hypercalcemia great 2.5 mmol/L For Hematologic malignancy : Marrow function characterize Neutrophil count less equal 500/mcl Platelets less equal 20,000/mcl 16 . HIVpositive patient 17 . Hepatitis C positive patient ( Hep C PCR positive ) 18 . Active Hepatitis B infection ( Hep B surface antigen positive ) 19 . Pregnant nursing 20 . Psychiatric illness/social situation would limit compliance study requirement ability comprehend investigational nature study provide inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 19, 2017</verification_date>
	<keyword>Metastatic Solid Tumor</keyword>
	<keyword>Chronic Myelogenous Leukemia ( CML )</keyword>
	<keyword>Small Lymphocytic Lymphoma ( SLL )</keyword>
	<keyword>Tumor Cytotoxicity</keyword>
	<keyword>Chronic Lymphocytic Leukemia ( CLL )</keyword>
	<keyword>Lung Cancer</keyword>
	<keyword>Prostate Cancer</keyword>
	<keyword>Colon Cancer</keyword>
	<keyword>Kidney Cancer</keyword>
	<keyword>Pancreatic Cancer</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Chronic Myelogenous Leukemia</keyword>
	<keyword>CML</keyword>
	<keyword>Small Lymphocytic Lymphoma</keyword>
	<keyword>SLL</keyword>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>CLL</keyword>
</DOC>